Arca
Skip to content
Tools
Tools

Monoamine transporter

Family in Homo sapiens that 11 drugs act on.

  • Drugs that act on it: 11
  • Approved: 4
  • In phases 1 to 3: 7
  • Sponsors: 10
  • Genes: 3

Who is on it, and how far along

Every drug ChEMBL records acting on SLC6A2, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 11

Approved4

  • Methamphetamine
  • Mazindol
  • Nomifensine
  • Sibutramine

Phase 33

  • Centanafadine
  • Bicifadine
  • Dasotraline

Phase 24

  • Amitifadine
  • Liafensine
  • NS-2359
  • Tesofensine

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Monoamine transporter inhibitor.
    MethamphetamineBoxed warningApprovedAjenat PharmaceuticalsSmall moleculeInhibitor53
    MazindolApprovedNovartis PharmaceuticalsSmall moleculeInhibitor0
    NomifensineWithdrawnApproved—Small moleculeInhibitor0
    SibutramineWithdrawnApprovedAbbott LaboratoriesSmall moleculeInhibitor0
    CentanafadinePhase 3Otsuka PharmaceuticalSmall moleculeInhibitor5
    BicifadinePhase 3DOV Pharmaceutical, Inc.Small moleculeInhibitor0
    DasotralinePhase 3Sumitomo PharmaSmall moleculeInhibitor0
    AmitifadinePhase 2Euthymics BioScience, Inc.Small moleculeInhibitor0
    LiafensinePhase 2Bristol-Myers SquibbSmall moleculeInhibitor0
    NS-2359Phase 2GSKSmall moleculeInhibitor0
    TesofensinePhase 2NeuroSearch A/SSmall moleculeInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 13 in all, from ClinicalTrials.gov.
    Sotatercept in the Treatment of Methamphetamine-Associated Pulmonary Arterial HypertensionMethamphetaminePhase 4Not yet recruitingOregon Health and Science UniversityNov 16, 2026
    Rehabilitation Program for People With Methamphetamine-Associated Cardiopulmonary ConditionsMethamphetamineNot applicableRecruitingMichael InczeNov 4, 2026
    Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for Insomnia During the Withdrawal-Rehabilitation Period of Methamphetamine Use DisorderMethamphetamineNot applicableNot yet recruitingThe First Affiliated Hospital of Zhejiang Chinese Medical UniversityOct 28, 2026
    Transcranial Magnetic Stimulation for Methamphetamine Use Disorder During PregnancyMethamphetamineNot applicableNot yet recruitingUniversity of UtahSep 30, 2026
    Randomized Controlled Trial of Tirzepatide for Methamphetamine Use DisorderMethamphetaminePhase 2RecruitingUniversity of Texas Southwestern Medical CenterSep 17, 2026
    Closed-loop tTIS Targeted of the Nac as an Intervention for MUD PatientsMethamphetamineNot applicableNot yet recruitingShanghai Mental Health CenterSep 3, 2026
    Closed-loop TBS Targeting rPO for the Core Clinical Features of Methamphetamine Use DisorderMethamphetamineNot applicableActive, not recruitingShanghai Mental Health CenterAug 20, 2026
    Psilocybin for Methamphetamine Use DisorderMethamphetaminePhase 2Not yet recruitingPeter HendricksAug 19, 2026
    A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional DysregulationCentanafadinePhase 3RecruitingOtsuka Pharmaceutical Development & Commercialization, Inc.Aug 12, 2026
    A Long-term Trial of EB-1020 in Pediatric Patients With ADHDCentanafadinePhase 3RecruitingOtsuka Pharmaceutical Co., Ltd.Jul 28, 2025
    A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHDCentanafadinePhase 2 / Phase 3RecruitingOtsuka Pharmaceutical Co., Ltd.Jul 25, 2025
    Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD PatientsCentanafadinePhase 2 / Phase 3RecruitingOtsuka Pharmaceutical Co., Ltd.Apr 16, 2025
    A Long-term Trial of EB-1020 in Adult Patients With ADHDCentanafadinePhase 3RecruitingOtsuka Pharmaceutical Co., Ltd.Apr 15, 2025

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2363064, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.